Skip to main content
BCPC logo

BCPC · Balchem Corp

Track BCPC — free
$168.73 -0.90 (-0.53%) At close · Nov 18
Market Cap
$5.36B
Shares
31.78M
Volume · Nov 18 211.1K Avg daily vol (3M) 249.28K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$168.73 Open$168.80 Day$167.84–169.69 52W close$147.36–183.26 Avg vol 30d294K Short int504K · 1.6% of shares · 1.5d Short vol55% Last earningsOct 23, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 23

Up next

Feb 19, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Oct 23
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Balchem reported third-quarter net sales of 290,658 and net earnings of 46,728, and nine-month net sales of 845,364 and net earnings of 131,628, all in thousands.

Revenue $290.66M ▲ 8.6% Net income $46.73M ▲ 16.0% Diluted EPS $1.46 ▲ 17.7%
Read from the MD&A section
Oct 23
Earnings call
Q3 2026 earnings call

Balcom Corporation reported record third-quarter consolidated revenue of $291 million, up 8.6%, and record adjusted EBITDA of $80 million, up 12.4%; net income was $47 million, up 16%, marking its 29th consecutive quarter of year-over-year adjusted EBITDA growth.

Oct 23
Current report 8-K
Financial results

Balchem Corporation reported third-quarter net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA of $80.3 million and free cash flow of $57.9 million for the quarter ended September 30, 2026.

Jul 31
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $284M ▲ 11.2% Net income $44.62M ▲ 16.6% Diluted EPS $1.39 ▲ 18.8%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.11B
Trailing 12 months
Net income (TTM)
$170.85M
Trailing 12 months
Revenue growth YoY
+8.6%
Year over year
Operating margin
20.7%
Trailing 12 months
P / E (TTM)
31.8
Trailing earnings · reciprocal yield 3.1%
FCF yield
—
TTM · current market cap
Return on invested capital
12.6%
Trailing 12 months
Net cash
−$81.27M
Latest balance sheet
Dividend yield
0.6%
Trailing 12 months
Shares change YoY
-1.7%
Year over year · fewer shares
Price change (1Y)
+9.6%
Trailing year
Short interest
1.6%
Latest settlement · 1.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 31, 2026
Q2 FY26

TL;DR. Balchem posted record Q2 2026 results with double-digit net sales and earnings growth across all three segments and refinanced its revolving credit facility to a larger $650M capacity maturing 2031. Animal Nutrition & Health led with 15% sales growth driven by both volume and pricing, helped by European anti-dumping duties that are restoring share.

Bullish
  • + Record consolidated Q2 results with net sales up 11.2% to $284.0M and adjusted EBITDA up 12.6% to $77.9M.
  • + All three segments delivered sales and earnings growth, with Human Nutrition & Health record sales up 10.0% to $176.9M and Specialty Products record sales up 8.9% to $40.5M.
  • + Refinanced and expanded revolving credit facility to $650M with maturity extended to July 2031, providing more capacity to fund growth and acquisitions.
  • + Returned $29M to shareholders via buybacks in Q2 ($114M over trailing twelve months) and paid down net debt to $88.8M with leverage ratio of 0.3x.
Bearish
  • − GAAP gross margin only expanded 10 bps to 36.5% as higher manufacturing input costs partially offset sales growth and efficiencies.
  • − Q2 effective tax rate rose to 22.8% from 21.9% in the prior-year quarter, due to lower tax benefits from stock-based compensation.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Sell Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very Low
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg −1%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 60%
mid-range
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +8%
trailing
YTD return +10%
this year
Relative strength +11%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $170 › 200d $170 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +55 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.58% of shares out · ▼ -2.6% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
431 holders — near 3-yr high, broad support
Squeeze score 44
elevated · 0–100
Fundamentals
Strong
Revenue growth +14%
Y/Y
Gross margin 46%
contracting
EPS growth +21%
Y/Y
Free cash flow $167.5M
Valuation P/E 31.8
in line
Balance sheet $112.6M
net debt
Quant / Vol
risk profile
Very Low
Volatility 22%
annualized · 1-yr
Max drawdown −15%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jul 31, 2020
Effective tax rate · full year 21% – 22%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
1 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
−1% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
60% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $170 › 200d $170 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +55 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.58% of shares out · ▼ -2.6% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
431 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $147 Now $169 · 60% Range high $183
vs 200-day avg -1% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted earnings from operations non-GAAP 192.49M Nine Months Ended September 30, 2026 —
Adjusted net earnings non-GAAP 141.44M Nine Months Ended September 30, 2026 —
EBITDA non-GAAP 214.14M Nine Months Ended September 30, 2026 —
Net debt non-GAAP 57.7M as of September 30, 2026 —
Overall leverage ratio non-GAAP 0.2 as of September 30, 2026 —
Adjusted earnings from operations, Human Nutrition and Health segment non-GAAP 45.9M the second quarter 2026 —
Common stock repurchases 29M the second quarter 2026 —
Common stock repurchases (trailing twelve months) 114M trailing twelve months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Specialty Chemicals — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BCPC
Balchem Corp
this stock
$5.36B +10.0% +13.6% 31.8 1.6%
LIN
Linde PLC
$235.12B +20.1% +3.0% 34.0 1.4%
AIQUF
L Air Liquide SA
$132.78B +10.8% — — 0.0%
ECL
Ecolab Inc.
$84.33B +14.5% +2.2% 40.9 1.5%
SHW
Sherwin Williams Co
$83.73B +7.0% +2.1% 31.9 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
431
% held
90.4%
Net QoQ
-245.5K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
386
View
Short & Settlement
Short Interest Falling
Shares short
503.6K
Days to cover
1.5d
Change
-13.4K sh
View
Short Volume
Short vol %
55%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
34
Value
$5.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jul 10, 2026
View
Financials
Financials
Revenue (FY)
$1.0B
Net income (FY)
$154.8M
EPS diluted
$4.75
View
Buybacks
Authorized
shares 4.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 23, 2026
This year
14

Balchem reported third-quarter net sales of 290,658 and net earnings of 46,728, and nine-month net sales of 845,364 and net earnings of 131,628, all in thousands.

View
Proposed Sales
Value
$919.7K
Shares
6.0K
Filed
Dec 4, 2025
View
Earnings & Events
Webcasts
Last webcast
Oct 23, 2026
View
Investor Relations
Latest news
Human Nutrition & Health | Animal…
Published
Oct 23, 2026
View

Performance

5D 20D 120D MTD YTD
BCPC -2.6% -1.2% +7.7% -0.7% +10.0%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.3% +4.4% +11.1% +2.6% +2.9%

Capital returns

Latest dividend
$0.96 / share · ex Dec 23, 2025
Declared · upcoming
$0.3984 / share · ex Dec 31, 2026
Raised 10.3%
Paid (TTM)
$0.96 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history
Buyback program · as of Dec 9, 2025
Authorized
shares 4.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 9326 CUSIP 057665200 13F (30d) 433 filings 396 filers Visit website